|
1
|
Steck PA, Pershouse MA, Jasser SA, et al:
Identification of a candidate tumour suppressor gene, MMAC1,
at chromosome 10q23.3 that is mutated in multiple advanced cancers.
Nat Genet. 15:356–362. 1997.PubMed/NCBI
|
|
2
|
Li J, Yen C, Liaw D, et al: PTEN, a
putative protein tyrosine phosphatase gene mutated in human brain,
breast, and prostate cancer. Science. 275:1943–1947. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Myers MP, Stolarov JP, Eng C, et al:
P-TEN, the tumor suppressor from human chromosome 10q23, is a
dual-specificity phosphatase. Proc Natl Acad Sci USA. 94:9052–9057.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Maehama T and Dixon JE: The tumor
suppressor, PTEN/MMAC1, dephosphorylates the lipid second
messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem.
273:13375–13378. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li DM and Sun H: PTEN/MMAC1/TEP1
suppresses the tumorigenicity and induces G1 cell cycle
arrest in human glioblastoma cells. Proc Natl Acad Sci USA.
95:15406–15411. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Robertson GP, Furnari FB, Miele ME, et al:
In vitro loss of heterozygosity targets the PTEN/MMAC1 gene
in melanoma. Proc Natl Acad Sci USA. 95:9418–9423. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Duerr EM, Rollbrocker B, Hayashi Y, et al:
PTEN mutations in gliomas and glioneuronal tumors. Oncogene.
16:2259–2264. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mallory SB: Cowden syndrome (multiple
hamartoma syndrome). Dermatol Clin. 13:27–31. 1995.PubMed/NCBI
|
|
9
|
Liaw D, Marsh DJ, Li J, et al: Germline
mutations of the PTEN gene in Cowden disease, an inherited
breast and thyroid cancer syndrome. Nat Genet. 16:64–67. 1997.
|
|
10
|
Di Cristofano A, Pesce B, Cordon-Cardo C,
Pandolfi PP, Cristofano AD and PP: Pten is essential for embryonic
development and tumour suppression. Nat Genet. 19:348–355.
1998.PubMed/NCBI
|
|
11
|
Yuan TL and Cantley LC: PI3K pathway
alterations in cancer: variations on a theme. Oncogene.
27:5497–5510. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Stambolic V, Suzuki A, Mirtsos C, et al:
Negative regulation of PKB/Akt-dependent cell survival by the tumor
suppressor PTEN. Cell. 95:29–39. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tamura M, Gu J, Matsumoto K, Aota S,
Parsons R and Yamada KM: Inhibition of cell migration, spreading,
and focal adhesions by tumor suppressor PTEN. Science.
280:1614–1617. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao X and Guan JL: Focal adhesion kinase
and its signaling pathways in cell migration and angiogenesis. Adv
Drug Deliv Rev. 63:610–615. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
He L, Ingram A, Rybak AP and Tang D:
Shank-interacting protein-like 1 promotes tumorigenesis via PTEN
inhibition in human tumor cells. J Clin Invest. 120:2094–2108.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gerlach B, Cordier SM, Schmukle AC, et al:
Linear ubiquitination prevents inflammation and regulates immune
signalling. Nature. 471:591–596. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tokunaga F, Nakagawa T, Nakahara M, et al:
SHARPIN is a component of the NF-κB-activating linear ubiquitin
chain assembly complex. Nature. 471:633–636. 2011.
|
|
18
|
Ikeda F, Deribe YL, Skånland SS, et al:
SHARPIN forms a linear ubiquitin ligase complex regulating NF-κB
activity and apoptosis. Nature. 471:637–641. 2011.PubMed/NCBI
|
|
19
|
Rantala JK, Pouwels J, Pellinen T, et al:
SHARPIN is an endogenous inhibitor of β1-integrin activation. Nat
Cell Biol. 13:1315–1324. 2011.PubMed/NCBI
|
|
20
|
Liang Y: Chronic proliferative dermatitis
in mice: NFκB activation autoinflammatory disease. Patholog Res
Int. 2011:9367942011.
|
|
21
|
Gijbels MJ, Hogenesch H, Blauw B, Roholl P
and Zurcher C: Ultrastructure of epidermis of mice with chronic
proliferative dermatitis. Ultrastruct Pathol. 19:107–111. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Seymour RE, Hasham MG, Cox GA, Shultz LD,
Hogenesch H, Roopenian DC and Sundberg JP: Spontaneous mutations in
the mouse Sharpin gene result in multiorgan inflammation, immune
system dysregulation and dermatitis. Genes Immun. 416–421. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Manning BD and Cantley LC: AKT/PKB
signaling: navigating downstream. Cell. 129:1261–1274. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xie Y, Yan J, Cutz JC, et al: IQGAP2, A
candidate tumour suppressor of prostate tumorigenesis. Biochim
Biophys Acta. 1822:875–884. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yan J, Wong N, Hung C, Chen WX and Tang D:
Contactin-1 reduces E-cadherin expression via activating AKT in
lung cancer. PLoS One. 8:e654632013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gilmore AP and Romer LH: Inhibition of
focal adhesion kinase (FAK) signaling in focal adhesions decreases
cell motility and proliferation. Mol Biol Cell. 7:1209–1224. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jung J, Kim JM, Park B, et al: Newly
identified tumor-associated role of human Sharpin. Mol Cell
Biochem. 340:161–167. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Greene G, Gilna P, Waterfield M, Baker A,
Hort Y and Shine J: Sequence and expression of human estrogen
receptor complementary DNA. Science. 231:1150–1154. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang X, Trotman LC, Koppie T, et al:
NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell.
128:129–139. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zanotto-Filho A, Braganhol E, Battastini
AM and Moreira JC: Proteasome inhibitor MG132 induces selective
apoptosis in glioblastoma cells through inhibition of PI3K/Akt and
NFkappaB pathways, mitochondrial dysfunction, and activation of
p38-JNK1/2 signaling. Invest New Drugs. 30:2252–2262. 2012.
View Article : Google Scholar
|
|
31
|
Vivanco I and Sawyers CL: The
phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev
Cancer. 2:489–501. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ghosh-Choudhury N, Mandal CC,
Ghosh-Choudhury N and Ghosh Choudhury G: Simvastatin induces
derepression of PTEN expression via NFκB to inhibit breast cancer
cell growth. Cell Signal. 22:749–758. 2010.PubMed/NCBI
|
|
33
|
Attwell S, Mills J, Troussard A, Wu C and
Dedhar S: Integration of cell attachment, cytoskeletal
localization, and signaling by integrin-linked kinase (ILK),
CH-ILKBP, and the tumor suppressor PTEN. Mol Biol Cell.
14:4813–4825. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mondal S, Subramanian KK, Sakai J, Bajrami
B and Luo HR: Phosphoinositide lipid phosphatase SHIP1 and PTEN
coordinate to regulate cell migration and adhesion. Mol Biol Cell.
23:1219–1230. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jin HO, An S, Lee HC, et al: Hypoxic
condition- and high cell density-induced expression of Redd1 is
regulated by activation of hypoxia-inducible factor-1α and Sp1
through the phosphatidylinositol 3-kinase/Akt signaling pathway.
Cell Signal. 19:1393–1403. 2007.PubMed/NCBI
|
